MGMT and glioblastoma: These studies include Checkmate-498 (NCT02617589) testing Nivolumab in MGMT unmethylated GBM, and Checkmate-548 testing Nivolumab in MGMT methylated GBM, in combination with standard chemoradiation therapy.35 While using hypermutation as a biomarker for ICI therapy has gained increased interest, standardized definition of this state of hypermutation has yet to be established.